ClinicalTrials.gg
RecruitingNCT06205797Updated Oct 3, 2024

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

A Phase 3 interventional study of HU-045 and Xeomin® in Glabellar Lines, sponsored by Huons Biopharma. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Huons Biopharma (part of Huons Global) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines

02

Conditions studied

  • Glabellar Lines
03

In context

Lead sponsor

Huons Biopharma is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 Years to 65 Years(Adult, Older Adult)
  • 2(Moderate) and/or above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment.
  • Subject who signed voluntarily in form and fully understood about this clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
  • History of bleeding disorder
  • Infection, dermatological condition or scar at the treatment injection sites
  • Subject who has marked facial asymmetry
  • History of facial nerve palsy or eyebrow/eyelid ptosis
  • History of surgical procedures affecting on the lines of forehead and/or middle of the forehead areas
  • History of malignant tumor within 5 years (except for basal cell carcinoma
  • Any disease and condition that, in the view of the investigator, would interfere with study participation
  • History of alcohol or drug addiction
  • Subject who has been treated with any botulinum toxin drug within 6 months
  • Persons who have received the following drugs with systemic muscle relaxant action within 4 weeks of screening
  • Subjects taking more than 1,000 IU/day of anticoagulants, antiplatelet agents, NSAIDs, or vitamin E within 7 days prior to administration of the drug (excluding low-dose aspirin)
  • A person who has received a retinoid series of medications during the following period as of the time of screening
  • Subjects who have reaction to investigational drug or local anesthetics
  • History of Anaphylaxis or severe combined allergy disease
  • Subject who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out
  • Pregnant and lactating women F- ertile women and men who have plans to pregnancy and who do not agree to appropriate .
  • Participant who has been treated with any investigational drug within 30 days from screening
  • Subject who are not eligible for this study based on investigator's judgement.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    HU-045 group

    HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each. HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered.

    Drug: HU-045

  • Active comparator
    Xeomin® group

    Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each. Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered.

    Drug: Xeomin®

Interventions

  • DrugHU-045

    HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. White powder Other Names: IncobotulinumtoxinA

  • Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA

06

What researchers measure

Primary outcomes

  1. Percentage of participants whose glabellar lines at maximal frown are improved

    Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.

    Time frame: Week4

Secondary outcomes

  1. Percentage of participants whose glabellar lines at maximal frown are improved

    Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.

    Time frame: Week8, Week12, Week16

  2. Percentage of participants whose glabellar lines at resting are improved

    Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at resting; 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.

    Time frame: Week4, Week8, Week12, Week16

  3. Subject's satisfaction rate after injection

    Participants will rate their overall satisfaction by answering the question on a Questionnaire using 7 point scale. 6 and/or above grade will be defined as the participant is satisfied about their glabellar lines; (1 = very unsatisfied, 2 = un satisfied, 3 = slightly dissatisfied, 4 = average, 5 = slightly satisfied, 6 = Satisfaction, 7 = very satisfied

    Time frame: Week4, Week8, Week12, Week16

  4. Percentage of subjects who assessed their Glabellar Lines are improved ≥ +2 grade

    Subjects will assess their glabellar Lines with a 9 point scale from -4 to +4;(+4 = 100% improvement, +3 = 75% improvement, +2 = 50% improvement, +1 = 25% improvement, 0 = no change, -1 = 25% worse, -2 = 50% worse, -3 = 75% worse, -4 = 100% worse

    Time frame: Week4, Week8, Week12, Week16

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Nov 2024, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 16, 2024
StartActual
Jun 20, 2024
Primary completionEst.
Nov 30, 2024
CompletionEst.
Mar 31, 2025
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205797
Lead sponsor
Huons Biopharma
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Jun 20, 2024
Primary completion
Nov 30, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Oct 3, 2024

Study contacts

Saeroarum Han
Contact
saeroarum@huonsbiopharma.com
82-70-7492-6032
Jiwon Kim
Contact
jw.kim@huonsbiopharma.com
82-70-7492-6074

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HU-045

Start the discussion